Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Isobutane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 5/20 | 0.34 |
| ▸ | CTSS | P25774 | 4/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isobutane SCHEMBL610709 | 0.97 | DGAT1 (0.39) | DGAT1CA1CA2CA7MEN1 | |
| Bicarbonate SCHEMBL29058152 | 0.91 | DGAT1 (0.42) | DGAT1CA1CA2CA7MEN1 | |
| SCHEMBL21436131 | 0.88 | DGAT1 (0.43) | DGAT1CA1CA2CA7MEN1 | |
| SCHEMBL74329 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL11841602 | 0.85 | — | — | |
| Methane SCHEMBL1718363 | 0.85 | — | — | |
| SCHEMBL9403851 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL7935492 | 0.85 | — | — | |
| Ethane SCHEMBL28346075 | 0.85 | DGAT1 (0.42) | DGAT1MEN1GAAKMT2ACTSK | |
| SCHEMBL3894529 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112028825-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-112028825-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-107683279-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| CN-106046007-B | Tyrosine kinase inhibitor and pharmaceutical composition comprising the tyrosine kinase inhibitor | 广东众生睿创生物科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |
| CN-107683279-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生药业股份有限公司 | 2018-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | ABL1, LCK, ERBB2 | DGAT1 3655/4885CA1 3462/4885CA2 1207/4885 |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | ABL1, LCK, ERBB2 | DGAT1 3655/4885CA1 3462/4885CA2 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.